About Guardiome
Guardiome is a Healthcare company based in San Diego (United States) founded in 2015 by Huwate Yeerna. It provides private genome sequencing, data delivery, and analysis tools for consumers. It operates on a D2C and B2C model. Its chief executive, as recorded, is Huwate Yeerna. Its Indian entity Thar Commercial Finance Private Limited reported revenue of ₹55.98 Cr. Guardiome offers products and services including Genome Sequencing Service, Genome Report, and Genome Explorer App. Its focus areas include Health, Biotech, Genomics and Genome Sequencing. Similar companies include 23andMe, Helix and Counsyl; 3 of its 3 listed similar companies have raised funding.
Company details
Guardiome, founded in 2015, specializes in private genome sequencing services with a focus on data privacy. Customers order kits online, submit samples, and receive secure genome files and reports after processing entirely on American soil. The company uses FDA-benchmarked bioinformatics for high-quality analysis and does not retain customer data, serving individuals through direct ordering or via physicians for health insights.
- Headquarters San Diego, United States
- Founders Huwate Yeerna
- SectorsHealthcare
- Email••••••••
- Website guardiome.com
- Social X Facebook
- Legal Name Thar Commercial Finance Private Limited
- Date of Incorporation 25 Jul, 2008
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹55.98 Cr
FY 2025 · +7% YoY
- Indian entity net profit₹5.93 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹48.21 Cr
FY 2025 · 86% margin
Associated legal entities of Guardiome
Guardiome operates through Thar Commercial Finance Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Thar Commercial Finance Private Limited CIN U65999MH2008PTC185082 | Active | 25 Jul 2008 | Mumbai, Maharashtra | ₹56.0 Cr | 4 | View details |
Products & Services of Guardiome
Guardiome offers a comprehensive portfolio of products and services, including Genome Sequencing Service, Genome Report, and Genome Explorer App.
Offers full genome sequencing with secure data delivery and privacy.
Provides in-depth reports on impactful genetic variants and consequences.
Enables users to search and analyze personal genome data via app.
Board of directors of Thar Commercial Finance Private Limited (Guardiome)
Thar Commercial Finance Private Limited is the primary company behind Guardiome. The board of Thar Commercial Finance Private Limited currently have 3 directors; the longest-serving is Vivek Jayesh Thar, appointed in 2015. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vivek Jayesh Thar DIN 06812365 | Director | 21 Feb 2015 | 11 yrs 8 mo | Thar Commercial Finance Private Limited |
| Chintan Hitendra Shah DIN 01376629 | Director | 21 Jan 2019 | 7 yrs 9 mo | Thar Commercial Finance Private Limited |
| Yatin Ajitrai Mankad DIN 00786683 | Director | 10 May 2021 | 5 yrs 6 mo | Thar Commercial Finance Private Limited |
People of Guardiome
1 people are tracked at Guardiome (1 in leadership).
| Name | Role | Group |
|---|---|---|
Huwate Yeerna | Founder, CEO | Leadership |
Complete people profiles for Guardiome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Guardiome
Figures of Thar Commercial Finance Private Limited, the primary company behind Guardiome, for FY 2025. Revenue was ₹55.98 Cr (+7% year on year). Net profit was ₹5.93 Cr (11% margin). EBITDA was ₹48.21 Cr (86% margin). Revenue has grown at a compounded annual rate of +9% over three years and 0% over five years.
- ₹55.98 CrRevenue · FY 2025 · +7% YoY
- ₹5.93 CrNet profit · 11% margin
- ₹48.21 CrEBITDA · 86% margin
- ₹49.96 CrPaid-up capital
- +9%Revenue CAGR, 3 years
- 0%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Thar Commercial Finance Private Limited are on its company page.
Detailed financial statements for Guardiome
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Guardiome
Guardiome has 3 listed similar companies in our database, 3 of them funded. They include 23andMe, Helix and Counsyl.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 23andme.com | 2006 | Sunnyvale, United States | $943.53M | 755 | Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | |
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| counsyl.com | 2007 | San Francisco, United States | $112.89M | 503 | DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening |
Detailed similar companies of Guardiome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical Genomics
3 companies that operate in the same segment as Guardiome (Clinical Genomics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Guardiome
Complete news archive for Guardiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Guardiome
Guardiome was founded in 2015.
Guardiome is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Huwate Yeerna is the CEO of Guardiome, as recorded in our data. They have also founded this company.
The primary company behind Guardiome, Thar Commercial Finance Private Limited, reported revenue of ₹55.98 Cr for FY 2025, up 7% year on year.
Guardiome, founded in 2015, specializes in private genome sequencing services with a focus on data privacy. Customers order kits online, submit samples, and receive secure genome files and reports after processing entirely on American soil. The company uses FDA-benchmarked bioinformatics for high-quality analysis and does not retain customer data, serving individuals through direct ordering or via physicians for health insights.
Guardiome offers Genome Sequencing Service, Genome Report, and Genome Explorer App.
Guardiome operates through Thar Commercial Finance Private Limited.
The legal entities of Guardiome currently have 4 directors, including Yatin Ajitrai Mankad, Vivek Jayesh Thar, Chintan Hitendra Shah and others.